Medical Oncology Department, Hospital Universitario "Virgen del Rocio", Seville, Spain.
Medical Oncology Department, Hôpital Universitaire Henri Mondor - Albert Chenevier, AP-HP, Créteil, France.
Cancer Treat Rev. 2017 Nov;60:77-89. doi: 10.1016/j.ctrv.2017.08.010. Epub 2017 Sep 1.
Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
肾癌约占所有新发癌症诊断的 5%。最常见的肾癌来源于肾上皮，称为肾细胞癌（RCC）。该实体包含不同的组织学和分子亚型。对 RCC 的分子生物学和细胞遗传学的研究，使几种靶向药物得以开发，从而改善了这些患者的治疗效果。本文综述了目前批准用于治疗 RCC 的所有药物，并讨论了即将出现的药物。对每种药物的作用机制、临床前和临床开发以及正在进行的试验进行了介绍，为 RCC 的靶向治疗的现状和可能的未来发展提供了全面的视角。
